HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...

The Indian market is expected to trade higher on January 15, supported by positive global cues. Nifty futures gained 0.51% on ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Biocon has experienced a significant earnings decline over the past two years, led by a lack of potential approvals for the U ...

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

Analysts said that assuming a $700 million market size for gAspart, Biocon can see US sales worth $25 million and $50 million ...

Shares of Biocon were in high demand on Monday after the pharmaceutical company's subsidiary Biocon Biologics' Johor Bahru ...

Zomato slips on Jefferies' downgrade, Biocon rallies on USFDA approval and Jefferies upgrade, ONGC gains as CLSA names it a ...

Biocon Ltd has broken out of the Symmetrical Triangle formation on daily charts, suggesting a potential rise in stock price.